Agios Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Brian Goff

Agios Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Brian Goff”): 45,757,238 for, 331,843 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 67 managers: 17,783,176 for, 8,657 withheld, 1 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1 managers: 2,704,900 for.

Description as filed by funds: To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Cynthia Smith

Agios Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Cynthia Smith”): 31,496,376 for, 14,592,704 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 68% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 67 managers: 10,265,833 for, 7,525,953 withheld, 49 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1 managers: 2,704,900 for.

Description as filed by funds: To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Rahul Ballal, Ph.D.

Agios Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Rahul Ballal, Ph.D.”): 40,145,081 for, 5,943,999 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 67 managers: 14,789,168 for, 3,002,648 withheld, 19 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1 managers: 2,704,900 for.

Description as filed by funds: TO APPROVE AN AMENDMENT TO THE AGIOS PHARMACEUTICALS, INC. 2023 STOCK INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE THEREUNDER BY 2,000,000 SHARES.

Agios Pharmaceuticals, Inc.’s own tally for this item (“3. The Company's stockholders approved the 2023 Plan Amendment.”): 43,549,751 for, 2,527,678 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the 2023 Plan Amendment.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 17,032,412 for, 757,478 against, 3,915 abstained.

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

Description as filed by funds: To vote, on an advisory basis, to approve the compensation paid to our named executive officers.

Agios Pharmaceuticals, Inc.’s own tally for this item (“2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”): 43,396,045 for, 1,086,059 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 67 managers: 17,554,726 for, 233,188 against, 3,921 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 204 managers: 30,919,487 for, 1,067,515 against, 1,576,681 abstained, 180 not voted, 693,118 mixed. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

Agios Pharmaceuticals, Inc.’s own tally for this item (“4. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.”): 48,511,213 for, 116,938 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 67 managers: 17,787,830 for, 89 against, 3,915 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1 managers: 2,704,900 for.